VBI Vaccines (VBIV)
(Delayed Data from NSDQ)
$0.09 USD
-0.02 (-18.97%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $0.08 -0.01 (-14.89%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for VBI Vaccines, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 1 | 1 | 1 | 2 |
Cost Of Goods | 13 | 11 | 11 | 9 | 8 |
Gross Profit | -4 | -10 | -10 | -8 | -6 |
Selling & Adminstrative & Depr. & Amort Expenses | 76 | 72 | 58 | 36 | 47 |
Income After Depreciation & Amortization | -80 | -82 | -68 | -44 | -52 |
Non-Operating Income | -7 | -27 | 3 | 0 | 0 |
Interest Expense | 6 | 4 | 5 | 3 | 2 |
Pretax Income | -93 | -113 | -70 | -46 | -55 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -93 | -113 | -70 | -46 | -55 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -93 | -113 | -70 | -46 | -55 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -76 | -78 | -63 | -40 | -50 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 5 | 3 | 2 |
Income After Depreciation & Amortization | -80 | -82 | -68 | -44 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 15.57 | 8.60 | 8.49 | 7.27 | 3.98 |
Diluted EPS Before Non-Recurring Items | -3.96 | -9.91 | -8.11 | -6.31 | -13.81 |
Diluted Net EPS (GAAP) | -6.03 | -13.21 | -8.11 | -6.31 | -13.81 |
Fiscal Year end for VBI Vaccines, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 1.21 | 0.85 | 6.62 | 0.72 |
Cost Of Goods | NA | 2.72 | 2.94 | 2.53 | 3.48 |
Gross Profit | NA | -1.51 | -2.09 | 4.10 | -2.76 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 10.24 | 11.28 | 14.17 | 34.21 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -11.75 | -13.37 | -10.07 | -36.97 |
Non-Operating Income | NA | -4.33 | 15.07 | -8.83 | -5.95 |
Interest Expense | NA | 1.82 | 1.72 | 1.54 | 1.71 |
Pretax Income | NA | -17.90 | -0.01 | -20.44 | -44.63 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -17.90 | -0.01 | -20.44 | -44.63 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -17.90 | -0.01 | -20.44 | -44.63 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 24.59 | NA | 21.17 | 8.61 |
Diluted EPS Before Non-Recurring Items | NA | -0.55 | NA | -0.38 | -2.17 |
Diluted Net EPS (GAAP) | NA | -0.73 | 3.38 | -1.01 | -5.18 |